natgillin/translations-raw huggingface dataset:
However, in a prospective study in healthy adult volunteers using doses of 200 mg lamotrigine and 1200 mg oxcarbazepine, oxcarbazepine did not alter the metabolism of lamotrigine and lamotrigine did not alter the metabolism of oxcarbazepine.
Toda v prospektivni študiji zdravih odraslih prostovoljcev, ki so jemali 200 mg lamotrigina in 1200 mg okskarbazepina, okskarbazepin ni spremenil presnove lamotrigina, lamotrigin pa ni spremenil presnove okskarbazepina.
In adults enrolled in studies utilizing the current lamotrigine dosing recommendations the incidence of serious skin rashes is approximately 1 in 500 in epilepsy patients.
V študijah, v katerih so lamotrigin uporabljali po trenutno veljavnih priporočilih za odmerjanje, je bila incidenca resnih izpuščajev na koži pri odraslih bolnikih z epilepsijo približno 1 na 500 primerov.
Additionally the overall risk of rash appears to be strongly associated with:
Poleg tega je tveganje za izpuščaj močno povezano z:
In another study, single oral doses of 600 mg carbamazepine significantly impaired fine visual motor co-ordination and eye movements, while increasing both body sway and heart rate, whereas results with lamotrigine at doses of 150 mg and 300 mg did not differ from placebo.
V drugi študiji so posamični peroralni odmerki 600 mg karbamazepina pomembno poslabšali fino vizualnomotorično koordinacijo in gibe oči ter povečali nihanje telesa in srčno frekvenco, učinki lamotrigina v odmerkih 150 mg in 300 mg pa se niso razlikovali od tistih pri placebu.
• For adults and children aged 13 years and over, Lamictal can be used on its own or with other medicines, to treat epilepsy.
• Odrasli in otroci od 13. leta naprej lahko jemljejo Lamictal sam ali skupaj z drugimi zdravili, in sicer za zdravljenje epilepsije.
Topiramate resulted in no change in plasma concentrations of lamotrigine.
Topiramat ni spremenil plazemske koncentracije lamotrigina.
Although changes in the plasma concentrations of other AEDs have been reported, controlled studies have shown no evidence that lamotrigine affects the plasma concentrations of concomitant AEDs.
Čeprav so poročali o spremembah v plazemskih koncentracijah drugih antiepileptikov, kontrolirane klinične študije niso pokazale vpliva lamotrigina na plazemsko koncentracijo sočasno uporabljenih antiepileptikov.
In double-blind, adjunctive clinical trials in adults, skin rashes occurred in up to 10% of patients taking lamotrigine and in 5% of patients taking placebo.
V dvojno slepih kliničnih preskušanjih pri odraslih je imelo izpuščaje do 10 % bolnikov, ki so jemali lamotrigin, in 5 % bolnikov, ki so jemali placebo.
Clinical efficacy in the prevention of mood episodes in patients with bipolar disorder
Klinična učinkovitost pri preprečevanju razpoloženjskih epizod pri bolnikih z bipolarno motnjo:
Rash has also been reported as part of a hypersensitivity syndrome associated with a variable pattern of systemic symptoms (see Immune system disorders**).
O izpuščaju so poročali tudi kot o delu preobčutljivostnega sindroma, ki ga spremljajo različne kombinacije sistemskih simptomov (glejte Bolezni imunskega sistema**).
In contrast, the mechanisms by which lamotrigine exerts its therapeutic action in bipolar disorder have not been established, although interaction with voltage gated sodium channels is likely to be important.
V nasprotju s tem mehanizem terapevtskega delovanja lamotrigina, mehanizem pri bipolarni motnji ni ugotovljen, čeprav je verjetno pomembno njegovo delovanje na napetostno aktivirane natrijeve kanale.
It is recommended that Lamictal not be restarted in patients who have discontinued due to rash associated with prior treatment with lamotrigine unless the potential benefit clearly outweighs the risk.
Bolnikom, ki so prenehali prejemati zdravilo Lamictal zaradi izpuščaja, ki je bil posledica predhodnega zdravljenjem z lamotriginom, tega zdravila ni priporočljivo ponovno uvesti, razen če možna korist nedvomno odtehta tveganje.
On average, approximately 20% (range = 5.6 to 35.1) of the amount of lamotrigine present in the body was eliminated during a 4-hour hemodialysis session.
V povprečju se je med 4-urno hemodializo izločilo približno 20 % (območje: od 5,6 do 35,1) v telesu prisotne količine lamotrigina.
In tests designed to evaluate the central nervous system effects of medicinal products, the results obtained using doses of 240 mg lamotrigine administered to healthy volunteers did not differ from placebo, whereas both 1000 mg phenytoin and 10 mg diazepam each significantly impaired fine visual motor co-ordination and eye movements, increased body sway and produced subjective sedative effects.
V testih za oceno učinkov zdravil na osrednje živčevje se učinki 240 mg odmerkov lamotrigina pri zdravih prostovoljcih niso razlikovali od učinkov placeba, odmerka 1000 mg fenitoina oz. 10 mg diazepama pa sta pomembno poslabšala fino vizualno-motorično koordinacijo in gibe oči, povečala nihanje telesa in povzročila subjektivne sedativne učinke.
The risk of congenital malformations is increased by a factor of 2 to 3 in the offspring of mothers treated with AEDs compared with the expected incidence in the general population of approximately 3%.
Pri otrocih mater, zdravljenih z antiepileptiki, je tveganje za kongenitalne malformacije 2- do 3-krat večje od pričakovane incidence med prebivalstvom na splošno, ki je približno 3 %.
500 mg/day has been required by some patients to achieve desired response
Nekateri bolniki so za želeni odziv potrebovali 500 mg/dan.
In a study of healthy volunteers, coadministration of felbamate (1200 mg twice daily) with lamotrigine (100 mg twice daily for 10 days) appeared to have no clinically relevant effects on the pharmacokinetics of lamotrigine.
V študiji zdravih prostovoljcev sočasna uporaba felbamata (1200 mg dvakrat na dan) in lamotrigina (100 mg dvakrat na dan 10 dni) ni klinično pomembno vplivala na farmakokinetiko lamotrigina.
The other side is marked with two overlapping super-ellipses at right angles.
Druga stran tablete pa je označena z dvema pravokotno postavljenima prekrivajočima se superelipsama.
White to off-white round tablet with a blackcurrant odour.
Bele do umazano bele okrogle tablete z vonjem po črnem ribezu.
• a high temperature (fever), flu-like symptoms or drowsiness
• zvišana telesna temperatura, gripi podobni simptomi ali zaspanost
Lamictal also treats bipolar disorder.
Lamictal zdravi tudi bipolarno motnjo
• changes which may show up in blood tests - including reduced numbers of red blood cells (anaemia), reduced numbers of white blood cells (leucopenia, neutropenia, agranulo-cytosis), reduced numbers of platelets (thrombocytopenia), reduced numbers of all these types of cell (pancytopenia), and a disorder of the bone marrow called aplastic anaemia
• spremembe, ki se lahko pokažejo pri preiskavah krvi, med njimi zmanjšano število rdečih krvnih celic (anemija), zmanjšano število belih krvnih celic (levkopenija, nevtropenija, agranulocitoza),
(Starter pack 42 tablets, monotherapy - calender pack showing day numbers): 1 2 3 4 5 6 7 (one pocket)
(Začetno pakiranje z 42 tabletami, monoterapija - koledarsko pakiranje z označenimi številkami dni): 1 2 3 4 5 6 7 (en žepek)
What Lamictal tablets contain
Kaj vsebujejo tablete Lamictal
If the calculated daily dose in patients taking valproate is less than 2.5 mg, then Lamictal should not be administered.>
Če je izračunani dnevni odmerek za bolnike, ki jemljejo valproat, manjši od 2,5 mg, Lamictala ne smete uporabljati.>
The transition regimen involves escalating the dose of lamotrigine to a maintenance stabilisation dose over six weeks (Table 3) after which other psychotropic medicinal products and/or AEDs can be withdrawn, if clinically indicated (Table 4).
V preglednici 3 je opisan režim 6-tedenskega zviševanja odmerka lamotrigina do vzdrževalnega stabilizacijskega odmerka (preglednica 3), ko je mogoče ukiniti zdravljenje s psihotropnimi zdravila in/ali antiepileptiki, če je to klinično indicirano (preglednica 4).
The overall risk of rash, appears to be strongly associated with:
Celotno tveganje za izpuščaj jemočno povezano z:
• an unusual skin reaction, such as redness or rashes
• nenavadna reakcija na koži, npr. pordelost ali izpuščaj,
DATE OF REVISION OF THE TEXT {MM/YYYY} [To be completed nationally]
DATUM ZADNJE REVIZIJE BESEDILA {MM. LLLL} [Izpolni država članica]
Lamictal is not indicated for the acute treatment of manic or depressive episodes”.
Zdravilo Lamictal ni indicirano za akutno zdravljenje maničnih ali depresivnih epizod“.
DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION {DD month YYYY} [To be completed nationally]
DATUM PRIDOBITVE/PODALJŠANJA DOVOLJENJA ZA PROMET {DD. mesec LLLL} [Izpolni država članica]
The most frequently reported defects are cleft lip, cardiovascular malformations and neural tube defects.
Najpogosteje opisane malformacije so heiloshiza, malformacije srca in ožilja in okvara nevralne cevi.
This dosage regimen should be used when valproate is added regardless of any concomitant medicinal products
Ta režim odmerjanja morate uporabiti po dodatku valproata, ne glede na morebitna sočasno uporabljana zdravila
If the calculated daily dose in patients taking valproate is less than 1 mg, then Lamictal should not be administered.>
Če je izračunani dnevni odmerek za bolnike, ki jemljejo valproat, manjši od 1 mg, Lamictala ne smete uporabljati.>
If you are taking Lamictal for bipolar disorder Lamictal may take some time to work, so you are unlikely to feel better straight away.
Pri zdravilu Lamictal lahko mine nekaj časa, preden začne delovati, zato ni verjetno, da se boste takoj počutili bolje.
Lamictal does not require any special storage conditions.
Za shranjevanje zdravila Lamictal niso potrebna posebna navodila.
hypersensitivity syndrome** (including such symptoms as, fever, lymphadenopathy, facial oedema, abnormalities of the blood and liver, disseminated intravascular coagulation, multi-organ failure).
preobčutljivostni sindrom** (vključno s simptomi, kot so zvišana telesna temperatura, limfadenopatija, edem obraza, nepravilnosti krvi in jeter, diseminirana intravaskularna koagulacija, večorganska odpoved)
Although the number of suicidal ideation and behaviour events was too low (6/1073 [0.6%] on lamotrigine and 2/805 [0.3%] on placebo) to allow a definitive comparison between treatment groups, the relative rate reported from this lamotrigine analysis is consistent with the reported class effect for AEDs (see section 4.4).
Število primerov samomorilnega razmišljanja in vedenja je bilo sicer premajhno (6/1073 [0,6 %] z lamotriginom in 2/805 [0,3 %] s placebom), da bi omogočilo dokončno primerjavo med terapevtskima skupinama.
Effects of lamotrigine on hormonal contraceptive efficacy An interaction study in 16 healthy volunteers has shown that when lamotrigine and a hormonal contraceptive (ethinyloestradiol/levonorgestrel combination) are administered in combination, there is a modest increase in levonorgestrel clearance and changes in serum FSH and LH (see section 4.5).
Vpliv lamotrigina na učinkovitost hormonskih kontraceptivov Študija medsebojnega delovanja pri 16 zdravih prostovoljkah je pokazala, da sočasna uporaba lamotrigina in hormonskega kontraceptiva (kombinacije etinilestradiola/levonorgestrela) povzroči zmerno povečanje očistka levonorgestrela in spremembe FSH in LH v serumu (glejte poglavje 4.5).
If you are using a hormonal contraceptive like the Pill, your doctor may take samples of your blood to check the level of Lamictal.
Če uporabljate hormonsko kontracepcijo, npr. kontracepcijske tablete, vas bo zdravnik morda napotil na preglede krvi, da bo preveril koncentracijo zdravila Lamictal.
Evidence from in vitro studies indicates that lamotrigine does not displace other AEDs from protein binding sites.
Ugotovitve študij in vitro kažejo, da lamotrigin ne izpodriva drugih antiepileptikov z beljakovinskih vezavnih mest.
Lamictal should not be given to people aged under 18 years to treat bipolar disorder.
Zdravila Lamictal za zdravljenje bipolarne motnje ne smejo dobivati bolniki, mlajši od 18 let.
Following titration, higher maintenance doses of lamotrigine (by as much as two-fold) will be needed in most cases to attain a maximal therapeutic response.
Po titriranju so večinoma potrebni večji (celo dvakratni) vzdrževalni odmerki lamotrigina, da je dosežen največji terapevtski odziv.
In the subset of epilepsy trials, there were no statistically significant differences in the rate of events between lamotrigine and placebo.
V podskupini preskušanj pri epilepsiji se delež teh pojavov med lamotriginom in placebom ni statistično značilno razlikoval.
Certain AEDs (such as phenytoin, carbamazepine, phenobarbitone and primidone) which induce hepatic drug-metabolising enzymes induce the glucuronidation of lamotrigine and enhance the metabolism of lamotrigine.
Nekateri antiepileptiki (npr. fenitoin, karbamazepin, fenobarbiton in primidon), ki inducirajo jetrne encime za presnovo zdravil, inducirajo glukuronidacijo lamotrigina in pospešijo njegovo presnovo.
1 - 10 mg/kg/day, although some patients have required higher doses (up to 15 mg/kg/day) to achieve desired response (once a day or two divided doses)
1-10 mg/kg/dan, vendar so nekateri bolniki za želeni odziv potrebovali večje odmerke (do 15 mg/kg/dan).
In single dose studies in subjects with end stage renal failure, plasma concentrations of lamotrigine were not significantly altered.
V študijah posamičnega odmerka pri preiskovancih z odpovedjo ledvic v zadnji fazi, se plazemska koncentracija lamotrigina ni pomembno spremenila.
There is no evidence that lamotrigine causes clinically significant induction or inhibition of hepatic oxidative drug-metabolising enzymes, and interactions between lamotrigine and medicinal products metabolised by cytochrome P450 enzymes are unlikely to occur.
Ni dokazov, da bi lamotrigin klinično pomembno induciral ali zaviral jetrne oksidacijske encime za presnovo zdravil, zato niso verjetne interakcije med lamotriginom in zdravili, ki se presnavljajo z encimi citokroma P450.
• phenytoin, primidone or phenobarbitone, used to treat epilepsy
• fenitoin, primidon ali fenobarbiton, ki se uporabljajo za zdravljenje epilepsije,
Lamictal is given as adjunctive therapy but may be the initial antiepileptic drug (AED) to start with in Lennox-Gastaut syndrome.
Zdravilo Lamictal se daje kot dopolnilno zdravljenje, lahko pa je tudi začetno antiepileptično zdravilo (AED) pri Lennox-Gastautovem sindromu.
• skin rashes or redness
• izpuščaj ali pordelost kože
After birth lamotrigine levels may increase rapidly with a risk of dose-related adverse events.
Po porodu se lahko koncentracija lamotrigina hitro poveča in obstaja tveganje za pojav neželenih učinkov, ki so odvisni od odmerka.
Study of the effect of lamotrigine on cardiac conduction
Raziskava vpliva lamotrigina na prevajanje v srcu
Someone who has taken too much Lamictal may have any of these symptoms:
Če vzamete preveč zdravila Lamictal, se vam lahko pojavi kateri od naslednjih simptomov:
Animal experiments did not reveal impairment of fertility by lamotrigine.
Poskusi na živalih niso pokazali vpliva lamotrigina na poslabšanje plodnosti.
Luxembourg GlaxoSmithKline s.a. Rue du Tilleul 13, B86
Luksemburg GlaxoSmithKline s.a. Rue du Tilleul 13, B86
Table 3: Adults aged 18 years and above - recommended dose escalation to the maintenance total daily stabilisation dose in treatment of bipolar disorder
Preglednica 3: Odrasli od 18. leta naprej - priporočeno zviševanje odmerka do vzdrževalnega celotnega dnevnega stabilizacijskega odmerka pri zdravljenju bipolarne motnje
Interactions involving other psychoactive agents
Medsebojno delovanje s psihoaktivnimi snovmi
25, 50, 100 and 200 mg tablets, 5, 25, 50, 100 and 200 mg dispersible/chewable tablets: Three years.
25-, 50-, 100- in 200 mg tablete, 5-, 25-, 50-, 100- in 200 mg disperzibilne/žvečljive tablete: 3 leta.
One side has a bevelled edge and is marked “LTG” above the number 2.
Na eni strani tablete s poševnim robom je napis "LTG" nad številko 2.
However, during prolonged human dosing, lamotrigine did not induce significant changes in the haemoglobin concentration, mean corpuscular volume, or serum or red blood cell folate concentrations up to 1 year or red blood cell folate concentrations for up to 5 years.
Vendar lamotrigin pri človeku med dolgotrajno uporabo do 1 leta ni pomembno spremenil koncentracije hemoglobina, povprečnega korpuskularnega volumna, koncentracije folata v eritrocitih ali v serumu, v obdobju 5 let pa ne koncentracije folata v eritrocitih.
• unexpected bleeding or bruising, or your fingers turning blue
• nepričakovana krvavitev ali podplutbe, ali pomodrelost prstov
Fertility Animal experiments did not reveal impairment of fertility by lamotrigine (see section 5.3).
Plodnost Poskusi na živalih niso pokazali, da bi lamotrigin vplival na plodnost (glejte poglavje 5.3).
Discontinuation of Lamictal in patients with bipolar disorder In clinical trials, there was no increase in the incidence, severity or type of adverse reactions following abrupt termination of lamotrigine versus placebo.
Ukinitev zdravila Lamictala pri bolnikih z bipolarno motnjo V kliničnih preskušanjih po nenadni prekinitvi lamotrigina niso ugotovili večje incidence, resnosti ali vrste neželenih učinkov kot pri placebu.
Mean clearances were 0.42 mL/min/kg (chronic renal failure), 0.33 mL/min/kg (between hemodialysis) and 1.57 mL/min/kg (during hemodialysis), compared with 0.58 mL/min/kg in healthy volunteers.
Povprečni očistki so bili 0,42 ml/min/kg (kronična odpoved ledvic), 0,33 ml/min/kg (v obdobju med hemodializami) in 1,57 ml/min/kg (med samo hemodializo).
Myoclonic seizures may be worsened by lamotrigine.
Lamotrigin lahko poslabša mioklonične napade.
Multiple oral doses of bupropion had no statistically significant effects on the single dose pharmacokinetics of lamotrigine in 12 subjects and had only a slight increase in the AUC of lamotrigine glucuronide.
Večkratni peroralni odmerki bupropiona pri 12 preiskovancih niso statistično značilno vplivali na farmakokinetiko lamotrigina po posamičnem odmerku, AUC lamotrigin-glukuronida pa se je le rahlo povečala.
hepatic failure, hepatic dysfunction, increased liver function tests.
odpoved jeter, moteno delovanje jeter, zvišani testi jetrnega delovanja.
Valproate, which inhibits the glucuronidation of lamotrigine, reduces the metabolism of lamotrigine and increases the mean half-life of lamotrigine nearly two-fold.
Valproat zavre glukuronidacijo lamotrigina, zmanjša njegovo presnovo in skoraj dvakrat podaljša povprečni razpolovni čas lamotrigina.
Lamictal is not indicated for the acute treatment of manic or depressive episodes.
Lamictal ni indiciran za akutno zdravljenje maničnih ali depresivnih epizod.
Lamictal is not recommended for use in children below 18 years of age due to a lack of data on safety and efficacy (see section 4.4).
Zaradi pomanjkanja podatkov o varnosti in učinkovitosti uporaba Lamictala ni priporočljiva pri otrocih do 18. leta starosti (glejte poglavje 4.4).
The proportion of subjects with treatment failure was 84% (16/19 subjects) in the placebo arm and 58% (11/19 subjects) in the lamotrigine arm.
V kraku s placebom je bil delež preiskovancev, pri katerih zdravljenje ni bilo uspešno, 84 % (16/19 preiskovancev), v kraku z lamotriginom pa 58 % (11/19 preiskovancev).
haematological abnormalities including neutropenia, leucopenia, anaemia, thrombocytopenia, pancytopenia, aplastic anaemia, agranulocytosis.
hematološke nepravilnosti, vključno z nevtropenijo, levkopenijo, anemijo, trombocitopenijo, pancitopenijo, aplastično anemijo in agranulocitozo.
700 mg/day has been required by some patients to achieve desired response
Nekateri bolniki so za želeni odziv potrebovali 700 mg/dan.
Lamotrigine 2 mg tablets are the lowest strength available, therefore the standard dosing schedule was adapted in some cases during the titration phase (for example, by administering a 2 mg tablet on alternate days when the calculated dose was less than 2 mg).
Zato so standardni razpored odmerjanja v nekaterih primerih med obdobjem titriranja prilagodili (npr. z uporabo ene 2 mg tablete vsak drugi dan, če je bil izračunani odmerek manjši od 2 mg).
UDP-glucuronyl transferases have been identified as the enzymes responsible for metabolism of lamotrigine.
Ugotovljeno je, da so za presnovo lamotrigina odgovorni encimi UDP-glukuronil-transferaze.
Lamotrigine has a slight inhibitory effect on dihydrofolic acid reductase and could therefore theoretically lead to an increased risk of embryofoetal damage by reducing folic acid levels (see section 4.4).
Lamotrigin rahlo zavira dihidrofolat-reduktazo in bi tako lahko z zmanjšanjem koncentracije folne kisline teoretično povzročil tveganje za embrio-fetalno okvaro (glejte poglavje 4.4).
Therefore, consideration should be given to using contraception without a pill-free week, as first-line therapy (for example, continuous hormonal contraceptives or non-hormonal methods; see sections 4.4 and 4.5).
Zato morajo imeti pri izbiri kontracepcije prednost načini, ki ne vključujejo tedna brez tablet (npr. stalni hormonski kontraceptivi ali nehormonski načini; glejte poglavji 4.4 in 4.5).
Effect of lamotrigine on hormonal contraceptive pharmacokinetics In a study of 16 female volunteers, a steady state dose of 300 mg lamotrigine had no effect on the pharmacokinetics of the ethinyloestradiol component of a combined oral contraceptive pill.
Vpliv lamotrigina na farmakokinetiko hormonskih kontraceptivov V študiji 16 prostovoljk, odmerek 300 mg lamotrigina v stanju dinamičnega ravnovesja ni vplival na farmakokinetiko etinilestradiola v kombinirani kontracepcijski tableti.
A modest increase in oral clearance of the levonorgestrel component was observed, resulting in an average 19% and 12% reduction in levonorgestrel AUC and Cmax, respectively.
Ugotovili so zmerno povečanje peroralnega očistka levonorgestrela, kar je povzročilo povprečno 19 % zmanjšanje AUC in povprečno 12 % zmanjšanje Cmax levonorgestrela.
Musculoskeletal and connective tissue disorders Very rare:
Bolezni mišično-skeletnega sistema in vezivnega tkiva Zelo redki:
Lamictal can also be used with other medicines to treat the seizures that occur with a condition called Lennox-Gastaut syndrome.
Zdravilo Lamictal se lahko jemlje skupaj z drugimi zdravili tudi za zdravljenje napadov krčev, ki se pojavljajo pri motnji, imenovani Lennox-Gastautov sindrom.
Multiple oral doses of lamotrigine 400 mg daily had no clinically significant effect on the single dose pharmacokinetics of 2 mg risperidone in 14 healthy adult volunteers.
Večkratni peroralni odmerki lamotrigina 400 mg na dan pri 14 zdravih odraslih prostovoljcih niso klinično pomembno vplivali na farmakokinetiko risperidona po posamičnem odmerku 2 mg.
Stopping hormonal contraceptives in patients already taking maintenance doses of lamotrigine and NOT taking inducers of lamotrigine glucuronidation The maintenance dose of lamotrigine will in most cases need to be decreased by as much as 50% (see sections 4.4 and 4.5).
Prenehanje uporabe hormonskih kontraceptivov pri bolnicah, ki že jemljejo vzdrževalne odmerke lamotrigina in NE jemljejo induktorjev glukuronidacije lamotrigina Vzdrževalni odmerek lamotrigina je večinoma treba znižatii, celo za 50 % (glejte poglavji 4.4 in 4.5).
As with other AEDs, abrupt withdrawal of Lamictal may provoke rebound seizures.
Kot velja za druge antiepileptike, lahko nenadna prekinitev Lamictala povzroči obratni odziv ("rebound") konvulzij.
The use of an ethinyloestradiol/levonorgestrel (30 µg/150 µg) combination increases the clearance of lamotrigine by approximately two-fold, resulting in decreased lamotrigine levels.
Uporaba kombinacije etinilestradiol/levonorgestrel (30 µg/150 µg) za približno dvakrat poveča očistek lamotrigina in tako zmanjša koncentracijo lamotrigina.
PVC/PVdC/aluminium foil blister.
Pretisni omot iz PVC/PVdC/aluminijske folije.
Lamotrigine has a slight inhibitory effect on dihydrofolic acid reductase, hence there is a possibility of interference with folate metabolism during long-term therapy (see section 4.6).
Lamotrigin rahlo zavira dihidrofolat-reduktazo, zato med dolgotrajnim zdravljenjem obstaja možnost ovirane presnove folata (glejte poglavje 4.6).